Table 1.

Effect of sorafenib tosylate against s.c. PLC/PRF/5 human HCC xenografts

Sorafenib tosylate (mg/kg/dose) *Experiment 1Experiment 2
Percent TGI [(1 − T/C) × 100], qd × 21Maximum percent net body weight lossPercent TGI [(1 − T/C) × 100], qd × 16Maximum percent net body weight loss
Control−21706
Vehicle017−78
1049 16
3078 , 1275 12
10082 (5/10 PR)16
  • * Sorafenib tosylate was administered p.o. once daily for 16 or 21 days at dose levels of 10, 30, and 100 mg/kg when all animals in the study had established tumors averaging from 140 to 160 mg.

  • P < 0.001, significantly different from the control group.

  • P < 0.001, significantly different from the 10 mg/kg dose level.